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Nasal potential difference (NPD) measurement can be an aid to diagnose CF and can
be used as outcome measure for multicenter trials. However, the NPD method should
meet certain standards to give accurate results. A wide variety of methodologies
are employed to measure NPD. Notable differences include (1) reference electrode
(subcutaneous or abrasion), (2) type and anatomic site of exploring electrode,
(3) warming of perfusate, (4) constituents of solutions.
To determine whether differences in procedures result in signiﬁcant disparity we
approached European CF centres and asked them to provide NPD tracings from 5
people with CF and 5 without.
Each centre used a distinct methodology. The traces were analysed independently
(IB) and average values for each centre generated. All centres established a clear
distinction between non-CF and CF, however there were signiﬁcant differences
between centres: in baseline PD values and in responses to low chloride and/or
isoproterenol solutions.
The diversity in the current NPD procedures means that it is not feasible now
to establish which factors are responsible for the differing results; however it is
clear from these data, that a standard international operating procedure is required
to further validate this technique, particularly if it is to be used as a surrogate
outcome measure for clinical trials.
Supported by: ECFS-DNWG/EUROCARECF WP3 diagnosis.
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Aim: Nasal potential difference(NPD) measurements are increasingly used as diagnos-
tic test as well as for evaluation of efﬁcacy of disease modifying drugs in cystic ﬁbrosis.
Several methods are used to measure NPD. The aim of this study was to explore the
inﬂuence of the position of the catheter on repeatability of NPD measurements.
Methods: NPD was measured twice over 12 weeks in 21 controls, using a slow Ringer’s
perfusion setup and Ag/AgCl electrodes. Simultaneously, PD was measured with a
PE50-catheter on the inferior surface of the inferior turbinate in one nostril and with
a modiﬁed Foley catheter along the nasal ﬂoor in the other. Basal PD was measured,
followed by response to perfusion with amiloride and with chlorefree solution without
and with isoproterenol. In 6 controls, the measurement was repeated 4 times in 1 week.
Tracings were discarded if unstable, ‘ﬂat’, or if catheter displacement occurred.
Results: Mean NPD results did not differ signiﬁcantly between ﬁrst and second mea-
surement. 95% limits of agreement between the repeated measurements were widely
spaced and similar with both methods. In the 4 measurements in 6 control subjects,
none of the methods showed a consitantly lower mean coefﬁcient of variation(CV)
across all parameters.
Conclusion: In control subjects, repeatability of NPD measurement under the inferior
turbinate and on the nasal ﬂoor is similar.
First and second measurement: mean (SD) and 95% limits of agreement in mV
Basal PD Amiloride response Total Cl secretion
Turbinate Floor Turbinate Floor Turbinate Floor
1st measurement −20 (8) −19 (7) 10 (6) 9 (4) −16 (14) −17(10)
2nd measurement −21(8) −18 (6) 9 (6) 7 (3) −18 (14) −14 (8)
95% limits of agreement −17 −15 −14 −12 −18 −19
(Bland Altman) 13 16 13 7 24 19
Mean CV of 4 NPD measurements in 6 controls
Basal PD Amiloride response Total Cl secretion
Turbinate Floor Turbinate Floor Turbinate Floor
mean CV 17% 31% 38% 29% 41% 36%
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Aim: Nasal potential difference(NPD) measurements are increasingly used as diag-
nostic test as well as for evaluation of efﬁcacy of disease modifying drugs in cystic
ﬁbrosis(CF). Several methods are used to measure NPD. The aim of this study was to
explore the inﬂuence of the position of the catheter on results obtained from NPD.
Methods: NPD was measured in 28 CF, 53 controls and 13 heterozygotes, using a slow
Ringer’s perfusion setup and Ag/AgCl electrodes. Simultaneously, PD was measured
with a PE50-catheter on the inferior surface of the inferior turbinate in one nostril
and, with a modiﬁed Foley catheter along the nasal ﬂoor of the other nostril. Basal PD
was measured, followed by response to perfusion with amiloride and with chlorefree
solution without and with isoproterenol. Tracings were discarded if unstable, ‘ﬂat’, or
if catheter displacement occurred.
Results: Number of interpretable tracings was similar with both techniques (turbinate
88/94, ﬂoor 81/94, McNemar test, p = 0.09). Variables mesured in each group did
not differ between methods (Wilcoxon test, p> 0.05). All variables measured differed
between CF and controls or heterozygotes (Kruskall-Wallis, post-hoc Dunn’s test,
p< 0.001), but not between heterozygotes and controls.
Conclusion: Simultaneous measurements of NPD on the nasal ﬂoor and under the
inferior turbinate showed similar success rates and similar results for basal PD, response
to amiloride and total chloride secretion.
Mean (SD) values in mV for measured NPD parameters
> Basal PD Amiloride response Total Cl secretion
Group Turbinate Floor Turbinate Floor Turbinate Floor
CF (n = 25) −46 (16) −45 (17) 31 (13) 29 (13) 3 (4) 3 (5)
Control
(n = 53)
−18 (8) −17 (6) 8 (5) 8 (4) −18 (12) −16 (9)
Heterozygote
(n = 11)
−16 (5) −13 (6) 8 (4) 7 (3) −17 (11) -14 (7)
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Sweat testing according to the guidelines is time-consuming and must be carried
out by experienced laboratories. New technologies that easily and rapidly measure
sweat chloride are of interest. EZscan® is a new patented technology using
low direct current voltage (<4V) generating reverse iontophoresis that allows
measurements of electrochemical skin conductance (ESC). ESC is linked to the
ion with the highest physiological concentration in sweat, i.e. chloride. Our aim
was to compare this new concept of sweat chloride measurement to the classical
sweat test. Measurements were performed in 31 adult patients with classical cystic
ﬁbrosis (CF) (13F, 18M; mean age±SD: 29±10 yrs) and 42 patients with non-
CF diffuse bronchiectasis (DB) (34F, 8M; mean age±SD: 52±17 yrs). ESC was
measured by the means of electrodes on each hand and foot. Sweat stimulation
was performed on the forearm by pilocarpine iontophoresis and sweat chloride
was measured by colorimetry. Sweat chloride concentrations evaluated by ESC
(mean±SD) were on the hands: 74±15 and 45±20mS and on the feet: 74±11
and 57±16mS in CF and DB patients, respectively (p< 0.0001 for all). Chloride
concentrations as measured by the sweat test were: 92±15 and 23±12mmol/L in
CF and DB patients, respectively (p< 0.0001). ESC diagnostic performance was
analyzed by ROC curve modelisation: ESC measurement provided a diagnostic
speciﬁcity of 0.91, a sensitivity of 0.86, with an area under ROC curve of 0.88.
EZscan® appears an attractive tool for measurement of sweat chloride: it requires no
patient preparation, no medical personnel training; it provides a quick measurement
(less than 2 min) and an immediate reading of the results. The study is ongoing in
healthy volunteers age-matching CF patients.
